---
title: "Merck and Moderna diverge on cancer vaccine results. Do they still have a viable drug?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302924282.md"
description: "Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data."
datetime: "2026-10-23T20:24:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302924282.md)
  - [en](https://longbridge.com/en/news/302924282.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302924282.md)
generator: "portal-rs"
---

# Merck and Moderna diverge on cancer vaccine results. Do they still have a viable drug?

Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%](https://longbridge.com/en/news/302763214.md)
- [Merck & Co Says FDA Accepts Priority Review For SAC-TMT Biologics License Application](https://longbridge.com/en/news/303113310.md)
- [Mizuho's Jared Holz: Moderna drop reflects high bar, not bad data](https://longbridge.com/en/news/302784303.md)
- [Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.](https://longbridge.com/en/news/302583219.md)
- [BUZZ-Moderna extends slide as analysts question valuation after cancer vaccine data](https://longbridge.com/en/news/302862405.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**